Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 120369143 | 12036914 | 3 | F | 20160127 | 20160422 | 20160208 | 20160902 | PER | US-ASTRAZENECA-2016SE09855 | ASTRAZENECA | 21869.00 | DY | F | Y | 78.50000 | KG | 20160902 | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 120369143 | 12036914 | 1 | PS | BYDUREON | EXENATIDE | 1 | Subcutaneous | 2 | MG | FT0054 | 22200 | 2 | MG | /wk | |||||
| 120369143 | 12036914 | 2 | SS | BYDUREON | EXENATIDE | 1 | Subcutaneous | 2 | MG | FT0054 | 22200 | 2 | MG | /wk | |||||
| 120369143 | 12036914 | 3 | SS | LISINOPRIL AND HYDROCHLOROTHIAZIDE | HYDROCHLOROTHIAZIDELISINOPRIL | 1 | Oral | 10-12.5 MG DAILY | 0 | TABLET | |||||||||
| 120369143 | 12036914 | 4 | SS | ONGLYZA | SAXAGLIPTIN HYDROCHLORIDE | 1 | Oral | 0 | 2.5 | MG | TABLET | QD | |||||||
| 120369143 | 12036914 | 5 | SS | ONGLYZA | SAXAGLIPTIN HYDROCHLORIDE | 1 | Oral | 5 MG PRN | 0 | TABLET | |||||||||
| 120369143 | 12036914 | 6 | SS | LISINOPRIL. | LISINOPRIL | 1 | Oral | 0 | 1025 | MG | TABLET | QD | |||||||
| 120369143 | 12036914 | 7 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | Oral | 0 | 500 | MG | BID | ||||||||
| 120369143 | 12036914 | 8 | C | BENADRYL | DIPHENHYDRAMINE HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 120369143 | 12036914 | 9 | C | RANITIDINE RELUX | 2 | 0 | 150 | MG | BID | ||||||||||
| 120369143 | 12036914 | 10 | C | MELOXICAM. | MELOXICAM | 1 | 0 | 15 | MG | QD | |||||||||
| 120369143 | 12036914 | 11 | C | ZANAFLEX | TIZANIDINE HYDROCHLORIDE | 1 | 4MG THREE TIMES A DAY AND AS NEEDED | 0 | |||||||||||
| 120369143 | 12036914 | 12 | C | ZYRTEC | CETIRIZINE HYDROCHLORIDE | 1 | 0 | 10 | MG | QD | |||||||||
| 120369143 | 12036914 | 13 | C | TRICOR | FENOFIBRATE | 1 | 0 | 145 | MG | QD | |||||||||
| 120369143 | 12036914 | 14 | C | VITAMIN D | CHOLECALCIFEROL | 1 | 2000U ONCE DAILY | 0 | |||||||||||
| 120369143 | 12036914 | 15 | C | LIPITOR | ATORVASTATIN CALCIUM | 1 | 0 | 40 | MG | QD | |||||||||
| 120369143 | 12036914 | 16 | C | ELAVIL | AMITRIPTYLINE HYDROCHLORIDE | 1 | 25MG AS NEEDED AT BEDTIME | 0 | |||||||||||
| 120369143 | 12036914 | 17 | C | PERCOCET | ACETAMINOPHENOXYCODONE HYDROCHLORIDE | 1 | 10-325 EVERY 4-6HRS, AS NEEDED | 0 | |||||||||||
| 120369143 | 12036914 | 18 | C | ALLERGY INJECTIONS | 2 | EVERY OTHER DAY | 0 | INJECTION | |||||||||||
| 120369143 | 12036914 | 19 | C | CLINDAMYCIN | CLINDAMYCINCLINDAMYCIN PHOSPHATE | 1 | 1% | 0 | |||||||||||
| 120369143 | 12036914 | 20 | C | PROVENTIL | ALBUTEROL | 1 | EVERY 4-6HRS, AS NEEDED, DAILY | 0 | NASAL SPRAY | ||||||||||
| 120369143 | 12036914 | 21 | C | ATORVASTATIN | ATORVASTATIN | 1 | Oral | 0 | 40 | MG | QD | ||||||||
| 120369143 | 12036914 | 22 | C | RANITIDINE. | RANITIDINE | 1 | Oral | 0 | 150 | MG | BID | ||||||||
| 120369143 | 12036914 | 23 | C | PROMETHAZINA | 2 | Oral | 0 | 25 | MG | QD | |||||||||
| 120369143 | 12036914 | 24 | C | MOVIC | 2 | Oral | 0 | 15 | MG | QD | |||||||||
| 120369143 | 12036914 | 25 | C | TIGANIBINE | 2 | Oral | 0 | 4 | MG | QD | |||||||||
| 120369143 | 12036914 | 26 | C | GABAPENTIN. | GABAPENTIN | 1 | Oral | 0 | 300 | MG | QD | ||||||||
| 120369143 | 12036914 | 27 | C | FLUTICASONE | FLUTICASONEFLUTICASONE PROPIONATE | 1 | Nasal | 0 | |||||||||||
| 120369143 | 12036914 | 28 | C | GLUCOSE | DEXTROSE | 1 | Oral | 0 | TABLET |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 120369143 | 12036914 | 1 | Type 2 diabetes mellitus |
| 120369143 | 12036914 | 2 | Diabetes mellitus |
| 120369143 | 12036914 | 3 | Hypertension |
| 120369143 | 12036914 | 4 | Type 2 diabetes mellitus |
| 120369143 | 12036914 | 5 | Type 2 diabetes mellitus |
| 120369143 | 12036914 | 6 | Hypertension |
| 120369143 | 12036914 | 7 | Type 2 diabetes mellitus |
| 120369143 | 12036914 | 8 | Sinus disorder |
| 120369143 | 12036914 | 11 | Muscle spasms |
| 120369143 | 12036914 | 17 | Pain |
| 120369143 | 12036914 | 21 | Blood cholesterol increased |
| 120369143 | 12036914 | 22 | Gastrooesophageal reflux disease |
| 120369143 | 12036914 | 23 | Nausea |
| 120369143 | 12036914 | 24 | Arthritis |
| 120369143 | 12036914 | 25 | Muscle spasms |
| 120369143 | 12036914 | 26 | Neuropathy peripheral |
| 120369143 | 12036914 | 27 | Multiple allergies |
| 120369143 | 12036914 | 28 | Blood glucose decreased |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 120369143 | 12036914 | Asthenia | |
| 120369143 | 12036914 | Back pain | |
| 120369143 | 12036914 | Blood glucose decreased | |
| 120369143 | 12036914 | Device defective | |
| 120369143 | 12036914 | Dizziness | |
| 120369143 | 12036914 | Fatigue | |
| 120369143 | 12036914 | Hyperhidrosis | |
| 120369143 | 12036914 | Injection site haemorrhage | |
| 120369143 | 12036914 | Injection site pain | |
| 120369143 | 12036914 | Nausea | |
| 120369143 | 12036914 | Pain |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 120369143 | 12036914 | 1 | 20160127 | 0 | ||
| 120369143 | 12036914 | 2 | 20160127 | 0 | ||
| 120369143 | 12036914 | 3 | 2004 | 0 | ||
| 120369143 | 12036914 | 4 | 20160111 | 201601 | 0 | |
| 120369143 | 12036914 | 7 | 2004 | 0 |